Virtual Screening – Finding needles in a haystack on a shoestring By Dr David E. Clark, Neil V. Harris, Alan G. Roach and Dr Anthony D. Baxter In recent years, virtual screening (VS) has become an accepted approach to hit-finding alongside biochemical high-throughput screening (HTS). Large pharmaceutical companies… Read More
Share Share Tweet Email Tools for Structural Genomics – Accelerating the structure pipeline Tools for Structural Genomics – Accelerating the structure pipeline By Dr Lawrence J. DeLucas, Dr Christie G. Brouillette, Dr Kal Ramnarayan and Dr… Read More
Opportunities for the pharmaceutical industry: key biotransformation technologies of the future By Praveen Kaul, Anirban Banerjee and Professor UC Banerjee Biotransformation is a broad and growing field of biotechnology and encompasses both enzymatic and microbial biocatalysis. Progress has been made in research on… Read More
Growing Market for High Content Analysis Tools By Dr. John Comley and Sandra Fox Two market surveys and a recent major scientific meeting have all highlighted the growing interest in High Content Screening (HCS) and point to the momentum which now surrounds the implementation of high content analysis… Read More
Functional cell-based high throughput drug screening By Professor Daniel T. Chiu and Professor Owe Orwar Cell-based assays are poised to assume an increasingly important role in drug screening and discovery. It is becoming apparent that simple binding assays and in vitro experiments are grossly insufficient for extrapolating… Read More
New developments in antigen-specific immunotherapies By Dr Jorg Schneider and Professor Andrew J. McMichael Novel therapeutic vaccines offer hope in the fight against chronic infectious disease and cancer. Vaccination has been used effectively for more than 200 years to protect individuals from a… Read More
Surface Plasmon Resonance’s impact on drug discovery – resolution, throughput and versatility By Dr David G. Myszka and Dr Rebecca L. Rich Surface plasmon resonance (SPR) biosensors have rapidly become a standard tool within the pharmaceutical and biotechnology industries. Label-free, real-time measurements are the calling card for this… Read More
Second-Generation Protein Drugs By Dr Jeffrey C.Way The first biotech revolution was catalysed in the late 1970s with the development of recombinant DNA technology. This revolution generated numerous billion-dollar protein drugs such as erythropoietin and the interferons. Now that the patents on these drugs… Read More
The importance of using human-based models in gene and drug discovery By Dr Michael G. Palfreyman, Dr Vinod Charles and Jeffrey Blander Completion of the human genome sequence has opened an unprecedented opportunity to discover the genetic contribution to many of the complex diseases that afflict humans and… Read More
Lead Generation and Lead Optimisation: the value of linking HT co-structure analysis and HT chemistry By Dr David U Prichard The coupling of High Throughput co-structure analysis with focused library generation is not only proving a powerful general tool in lead optimisation but also increasing the probability of… Read More
Chemical microarrays – The drug discovery superhighway By Elaine Seeskin While producing targets was once the bottleneck in the drug discovery process, in the post-genomic era this has been superseded by the requirement for high-quality lead structures. As a result of the pool… Read More
Silicon Technology and Pharmaceutics by Professor Leigh T. Canham, Dr Roghieh S. Saffie, Stephen E. Connor and Dr Roger Aston The recent discovery that, following nanostructuring, silicon can be rendered biocompatible and biodegradable has far reaching and profound long-term implications for the pharmaceutical industry and, indeed, medicine as… Read More
New Developments in Analgesia By Dr Susan Boyce, Dr Zahid Ali and Dr Raymond G. Hill Novel therapies for pain and headache are major medical needs and constitute a continued opportunity. Novel treatments are likely to arise from a better understanding of both the pathophysiology of clinical… Read More
By Professor Klaus Lindpaintner Pharmacogenetics represents a logical and consequent step in the history of medicine, but what are the immediate benefits and where do the hurdles lie in its implementation? It is common knowledge that today’s pharmacopea – in as much… Read More
e-R&D – The internet at work By Dr Alpheus Bingham and Dr Neil Bodick It is difficult to understand how the continuing growth of large monolithic Research & Development organisations can sustain the industry. With the economies of scale providing diminishing returns we examine the promise of… Read More
Discovery Research in the Co-Genomic Era – Biology goes industrial By Dr Timothy Wells and Dr Georg Feger The parallel between the search for gold in the last century and drug discovery in the co-genome era is very clear. As with all gold rushes the rewards will… Read More